TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Biologic Innovation | Explore TELA Bio's pioneering OviTex mesh for hernia repair, offering biocompatibility and cost-effectiveness over traditional plastic alternatives |
Market Dynamics | Delve into TELA Bio's position amidst the industry shift from plastic to biologic mesh, and its potential for significant market share gains |
Financial Outlook | Learn about TELA Bio's revenue projections, with analyst estimates ranging from $105.5 million to $115 million for 2026, despite current profitability challenges |
Strategic Challenges | Uncover TELA Bio's response to aggressive competitor tactics, including sales force refinements and a $5-10 million cost reduction plan for 2025 |
Metrics to compare | TELA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTELAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.7x | −3.6x | −0.6x | |
PEG Ratio | −0.04 | −0.19 | 0.00 | |
Price/Book | 7.4x | 2.8x | 2.6x | |
Price / LTM Sales | 0.9x | 3.5x | 3.3x | |
Upside (Analyst Target) | 233.9% | 19.7% | 40.1% | |
Fair Value Upside | Unlock | 13.9% | 5.3% | Unlock |